PJP ETF Analysis: Dynamic Pharmaceuticals | NYSE
Healthcare Equity | NYSE, USA | Market Cap: 582m USD | 12M Return: 34% | US46137V6627 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.91M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Invesco Dynamic Pharmaceuticals ETF (PJP) is a U.S.-listed exchange-traded fund that tracks an underlying index of 30 American pharmaceutical companies. The fund invests at least 90% of its total assets in the securities of this index, focusing on firms engaged principally in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs. PJP is structured as a non-diversified fund and falls within the healthcare ETF category, targeting a specific segment of the broader health sector rather than the industry as a whole.
The pharmaceutical sector operates under a distinctive business model centered on the discovery, patenting, and commercialization of drug compounds, with revenue often protected by intellectual property rights and shaped by regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA). Companies in this space typically face long development timelines and significant R&D costs before bringing products to market.
- Medicare drug price negotiations expand under Inflation Reduction Act
- FDA approval pipeline momentum lifts pharmaceutical revenue outlook
- Patent cliff expirations pressure top portfolio holdings revenue
As of November 11, 2026, the stock is trading at USD 130.54 with a total of 10,206 shares traded. Over the past week, the price has changed by +1.11%, over one month by +5.75%, over three months by +4.31% and over the past year by +34.03%.
Current recommended Stop Loss: 127.30 (which is 2.5% or 1.3 ATR below the current price).
Dynamic Pharmaceuticals has no consensus analysts rating.